Pfizer

PANZYGA (Immune Globulin Intravenous [Human] – ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older, chronic immune thrombocytopenia (cITP) in adults and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.

PANZYGA is a liquid medicine for infusion that contains immunoglobulin G (IgG), which are proteins that help fight infection. It is made from human plasma that is donated by healthy people and contains antibodies. For patients with PI, PANZYGA helps replace the missing antibodies in the body. For patients with cITP, PANZYGA helps the body produce more platelets (the blood cells that help blood clot) to control or prevent bleeding. For patients with CIDP, PANZYGA may help improve mobility and hand strength.

PANZYGA is given into a vein (intravenously) in a hospital, infusion center, doctor’s office, or at home by a trained healthcare provider (HCP).

WARNING: THROMBOSIS, RENAL DYSFUNCTION, and ACUTE RENAL FAILURE

See Full Prescribing Information, including complete BOXED WARNING, below.

• Thrombosis may occur with immune globulin intravenous (IGIV) products, including PANZYGA. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
• Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. PANZYGA does not contain sucrose.
• For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer PANZYGA at the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

• Have had a severe allergic reaction to immune globulin or other blood products
• Have a condition called selective (or severe) immunoglobulin A (IgA) deficiency, with antibodies against IgA and a history of hypersensitivity

• PANZYGA can make vaccines (like measles/mumps/rubella or chickenpox vaccines) work less effectively for you. Before you get any vaccines, tell your healthcare provider that you take PANZYGA
• Decreased kidney function and kidney function failure can occur
• Severe headache, drowsiness, fever, painful eye movements, or nausea and vomiting can occur
• Elevated blood pressure can occur particularly in patients who have a history of hypertension (high blood pressure)
• If you are elderly, with heart or kidney problems, discuss with your healthcare provider prior to initiating treatment with PANZYGA 
• PANZYGA is made from human blood and therefore may have a risk of transmitting infectious agents, including viruses and, theoretically, the variant Creutzfeldt-Jakob disease (CJD) and CJD agent. The production and manufacturing process reduces this risk, but the risk cannot be eliminated

• Hives, swelling in the mouth or throat, itching, trouble breathing, wheezing, fainting, or dizziness. These could be signs of a serious allergic reaction
• Bad headache with nausea, vomiting, stiff neck, fever, drowsiness, painful eye movements, and sensitivity to light. These could be signs of irritation and swelling of the lining around your brain
• Reduced urination, sudden weight gain, or swelling in your legs. These could be signs of a kidney problem (decreased kidney function or kidney failure)
• Pain, swelling, warmth, redness, or a lump in your legs or arms. These could be signs of a blood clot, which could happen in the heart, brain, lungs, or elsewhere in the body
• Brown or red urine, swelling, fatigue, fast heart rate, difficulty breathing, or yellow skin or eyes. These could be signs of a liver or blood problem
• Chest pain or trouble breathing, or blue lips or extremities. These could be signs of a serious heart or lung problem
• Fever over 100°F. This could be a sign of an infection
• Headache, fatigue or confusion, vision problem, chest pain, difficulty breathing, irregular heartbeat, or pounding in your chest, neck, or ears. These could be signs of high blood pressure  

Ask your HCP whether you should have rescue medications available, such as antihistamines or epinephrine.

The most common side effects that may occur with PANZYGA are:

• Headache
• Nausea
• Fever
• Increased blood pressure
• Dermatitis
• Fatigue
• Abdominal pain
• Dizziness
• Anemia 

These are not all the possible side effects. Talk to your HCP about any side effect that bothers you or that does not go away. 

Tell your HCP if you are pregnant, or plan to become pregnant, or if you are nursing.  

PANZYGA is an FDA-approved IVIg therapy to treat adults with CIDP or cITP, and people 2 years of age and older with PI.

• For adults with CIDP, PANZYGA may help improve arm and leg strength and mobility and general activity level
• For people 2 years of age and older with PI, PANZYGA helps replace antibodies that are missing from the immune system, which may help reduce the risk of infection
• For adults with cITP, PANZYGA helps boost platelet count, which may help control and prevent bleeding 

PANZYGA is a liquid medicine given by infusion that contains purified antibodies known as immunoglobulin G (IgG).

PANZYGA offers resources to help support patients on their IVIg therapy journey.

Pfizer IGuide^TM can help you understand your insurance coverage and out-of-pocket costs for your prescribed PANZYGA, as well as identify financial assistance options for which you may be eligible.

If you have been prescribed PANZYGA and have questions about your coverage, call Pfizer IGuide^TM Monday through Friday, 8 AM to 8 PM ET, at
1-844-448-4337.

Financial Assistance

• Pfizer IGuide^TM can help identify financial assistance resources for which you may be eligible to help with out-of-pocket costs for PANZYGA

Commercially Insured Patients

• If you have commercial, employer, or private coverage, including coverage purchased through a state health insurance marketplace, you may be eligible for the PANZYGA Co-Pay Program, which can help cover the cost of your co-pay. Eligible patients may pay as little as $0 per PANZYGA treatment. The value of the co-pay card is limited to a maximum of $5000* per calendar year

Medicare/Government-Insured Patients 

• If you have government-funded insurance and need help to cover the cost of PANZYGA, Pfizer IGuide^TM can help identify financial support options including alternate coverage resources, if available 

Uninsured Patients 

• If you do not have health insurance and cannot afford PANZYGA treatment, Pfizer IGuide^TM can connect you to potential resources that may help cover the cost of PANZYGA, including how to apply to Medicaid if you may be eligible 

Visit www.PfizerIGuide.com to learn more.

*Terms and conditions/eligibility requirements apply. See full terms and conditions here. Patients must be 2 years or older and have commercial insurance to be eligible. Patients are not eligible if they are enrolled in a state or federally funded insurance program.

Learn more about CIDP, PANZYGA treatment, and the support available to you. 

Learn more about PANZYGA and getting started on IVIg therapy. 

Document your treatment experience after each PANZYGA infusion.

Learn more about the financial resources that may be available to you.

---

You may be eligible for financial assistance options to help with out-of-pocket costs, including the PANZYGA Co-Pay Program, which can help cover the cost of your co-pay. Watch now to learn more.